Literature DB >> 9042433

IL-4 synergizes with IL-10 and anti-CD40 MoAbs to induce B-cell differentiation in patients with common variable immunodeficiency.

J Punnonen1, L Kainulainen, O Ruuskanen, J Nikoskelainen, H Arvilommi.   

Abstract

In the present study the phenotype and function of lymphocytes from patients with common variable immunodeficiency (CVI) were studied. Five out of 12 patients had abnormally low proportion of CD4+ T cells, but PBMC of these patients were capable of proliferating in response to polyclonal T-cell mitogens or PPD antigen. The phenotype of patients' B cells, as determined by expression of CD10, CD19 and CD34, was comparable to that of healthy controls. IL-4 and anti-CD40 MoAbs induced moderate B-cell differentiation in PBMC derived from patients with CVI, but the frequencies of Ig-secreting cells were generally at levels spontaneously observed in healthy controls. IL-10 was completely ineffective in inducing IgG-secreting cells in cultures of PBMC derived from patients with CVI even in the presence of anti-CD40 MoAbs, whereas high frequencies of Ig-secreting cells were induced under similar condition in cultures of PBMC derived from healthy controls. Importantly, when IL-4 was added to cultures stimulated with anti-CD40 MoAbs and IL-10, a very strong synergistic effect on the numbers of Ig-secreting cells and the levels of Ig secretion was observed in PBMC from both patients and controls. Moreover, the frequencies of Ig-secreting cells after activation with anti-CD40 MoAbs, IL-4 plus IL-10 in PBMC from some patients were comparable to those observed in PBMC from healthy controls. Taken together, these results indicate that B cells from patients with CVI have impaired capacity to differentiate into Ig-secreting cells in response to IL-10 and anti-CD40 MoAbs, and that this unresponsiveness can be restored by exogenous IL-4 in a proportion of the patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9042433     DOI: 10.1046/j.1365-3083.1997.d01-381.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  7 in total

1.  Elevated serum interleukin (IL)-12p40 levels in common variable immunodeficiency disease and decreased peripheral blood dendritic cells: analysis of IL-12p40 and interferon-gamma gene.

Authors:  N Martinez-Pomar; S Raga; J Ferrer; J Pons; I Munoz-Saa; M-R Julia; J de Gracia; N Matamoros
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

2.  Age dependency and mutual relations in T and B lymphocyte abnormalities in common variable immunodeficiency patients.

Authors:  M Vlková; V Thon; M Sárfyová; L Bláha; A Svobodník; J Lokaj; J Litzman
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

3.  IL-10 and IL-4 co-operate to normalize in vitro IgA production in IgA-deficient (IgAD) patients.

Authors:  M Marconi; A Plebani; M A Avanzini; R Maccario; A Pistorio; M Duse; M Stringa; V Monafo
Journal:  Clin Exp Immunol       Date:  1998-06       Impact factor: 4.330

4.  A double-blind, placebo-controlled, crossover therapy study with natural human IL-2 (nhuIL-2) in combination with regular intravenous gammaglobulin (IVIG) infusions in 10 patients with common variable immunodeficiency (CVID).

Authors:  J A Rump; A Jahreis; M Schlesier; S Stecher; H H Peter
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

Review 5.  Common variable immunodeficiency.

Authors:  W Strober; K Chua
Journal:  Clin Rev Allergy Immunol       Date:  2000-10       Impact factor: 10.817

6.  Diagnostic findings in 95 Finnish patients with common variable immunodeficiency.

Authors:  L Kainulainen; J Nikoskelainen; O Ruuskanen
Journal:  J Clin Immunol       Date:  2001-03       Impact factor: 8.542

7.  Regulatory T cell dysfunction in subjects with common variable immunodeficiency complicated by autoimmune disease.

Authors:  Grace P Yu; David Chiang; Steven J Song; Elisabeth G Hoyte; Jennifer Huang; Christopher Vanishsarn; Kari C Nadeau
Journal:  Clin Immunol       Date:  2009-01-22       Impact factor: 3.969

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.